MA53873A - Compositions et procédés pour le traitement de la presbytie - Google Patents
Compositions et procédés pour le traitement de la presbytieInfo
- Publication number
- MA53873A MA53873A MA053873A MA53873A MA53873A MA 53873 A MA53873 A MA 53873A MA 053873 A MA053873 A MA 053873A MA 53873 A MA53873 A MA 53873A MA 53873 A MA53873 A MA 53873A
- Authority
- MA
- Morocco
- Prior art keywords
- presbyopia
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743720P | 2018-10-10 | 2018-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53873A true MA53873A (fr) | 2022-01-19 |
Family
ID=70161531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053873A MA53873A (fr) | 2018-10-10 | 2019-10-08 | Compositions et procédés pour le traitement de la presbytie |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10836760B2 (fr) |
| EP (1) | EP3863630A4 (fr) |
| JP (1) | JP2022504746A (fr) |
| KR (1) | KR20210076941A (fr) |
| CN (1) | CN113518620A (fr) |
| AU (1) | AU2019357979A1 (fr) |
| BR (1) | BR112021006618B1 (fr) |
| CA (1) | CA3114204A1 (fr) |
| MA (1) | MA53873A (fr) |
| MX (1) | MX2021004183A (fr) |
| SG (1) | SG11202103033WA (fr) |
| WO (1) | WO2020076769A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210338666A1 (en) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Brimonidine combinations and uses thereof |
| EP4228636A1 (fr) * | 2020-10-13 | 2023-08-23 | Lenz Therapeutics, Inc. | Compositions et procédés pour des médicaments ophtalmiques stables au stockage |
| WO2022232205A1 (fr) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | Procédé de réduction de douleur de sourcil |
| CN116459251A (zh) * | 2022-01-18 | 2023-07-21 | 苏州普乐康医药科技有限公司 | 一种含西维美林的眼用制剂及其制备方法和应用 |
| TW202329958A (zh) * | 2022-01-25 | 2023-08-01 | 張金明 | 西維美林水溶液組合物和使用方法 |
| US20230310380A1 (en) * | 2022-04-05 | 2023-10-05 | Alan Neil Glazier | Methods, devices, and systems for treating lens protein aggregation diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0632649B2 (ja) * | 1986-02-20 | 1994-05-02 | ロ−ト製薬株式会社 | 液状医薬品包装体 |
| EP0648118A1 (fr) * | 1992-07-02 | 1995-04-19 | Telor Ophthalmic Pharmaceuticals, Inc. | Procedes et produits permettant de traiter la presbytie |
| JP3849736B2 (ja) * | 1998-04-13 | 2006-11-22 | ライオン株式会社 | 易酸化物質又はこれを含む組成物の包装体及び易酸化物質の安定化方法 |
| US20090297566A1 (en) * | 2004-12-27 | 2009-12-03 | Brinkman Kyle R | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions |
| US9320709B2 (en) * | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US10307408B2 (en) * | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US20190038609A1 (en) * | 2013-08-28 | 2019-02-07 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| CA2987787C (fr) * | 2015-06-18 | 2023-06-27 | Presbyopia Therapies, LLC | Compositions pour l'amelioration de la vision de loin et pour le traitement de l'ametropie de l'oeil |
| US20190022059A1 (en) * | 2015-09-24 | 2019-01-24 | Encore Vision, Inc. | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations |
| JP6996713B2 (ja) * | 2015-10-06 | 2022-02-04 | エイチエルビー・セラピューティクス・カンパニー・リミテッド | チモシンベータ４を含む眼科用製剤の製造方法 |
| CA3017755A1 (fr) * | 2016-03-17 | 2017-09-21 | Presbyopia Therapies, LLC | Compositions et methodes de traitement de la presbytie |
-
2019
- 2019-10-08 AU AU2019357979A patent/AU2019357979A1/en active Pending
- 2019-10-08 CA CA3114204A patent/CA3114204A1/fr active Pending
- 2019-10-08 CN CN201980067359.1A patent/CN113518620A/zh active Pending
- 2019-10-08 KR KR1020217014044A patent/KR20210076941A/ko unknown
- 2019-10-08 WO PCT/US2019/055116 patent/WO2020076769A1/fr active Application Filing
- 2019-10-08 MX MX2021004183A patent/MX2021004183A/es unknown
- 2019-10-08 SG SG11202103033WA patent/SG11202103033WA/en unknown
- 2019-10-08 MA MA053873A patent/MA53873A/fr unknown
- 2019-10-08 BR BR112021006618-7A patent/BR112021006618B1/pt active IP Right Grant
- 2019-10-08 US US16/595,789 patent/US10836760B2/en active Active
- 2019-10-08 EP EP19871827.2A patent/EP3863630A4/fr active Pending
- 2019-10-08 JP JP2021519886A patent/JP2022504746A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3863630A1 (fr) | 2021-08-18 |
| SG11202103033WA (en) | 2021-04-29 |
| WO2020076769A1 (fr) | 2020-04-16 |
| CN113518620A (zh) | 2021-10-19 |
| KR20210076941A (ko) | 2021-06-24 |
| US10836760B2 (en) | 2020-11-17 |
| US20200115377A1 (en) | 2020-04-16 |
| AU2019357979A1 (en) | 2021-04-29 |
| EP3863630A4 (fr) | 2022-06-29 |
| BR112021006618A2 (pt) | 2021-07-06 |
| BR112021006618B1 (pt) | 2022-09-27 |
| MX2021004183A (es) | 2021-10-26 |
| JP2022504746A (ja) | 2022-01-13 |
| CA3114204A1 (fr) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
| MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
| MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
| MA51103A (fr) | Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA51306A (fr) | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase | |
| MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| MA41044A (fr) | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer | |
| MA53558A (fr) | Compositions et procédés pour le traitement d'infections virales | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA53445A (fr) | Procédés et compositions pour la modification de plantes | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA55087A (fr) | Compositions et procédés de traitement de laminopathies | |
| MA52199A (fr) | Compositions et procédés de traitement de la dystrophie maculaire | |
| MA55093A (fr) | Méthodes et compositions pour le traitement du cancer |